ARGX cites Vision 2030 targets and immunology pipeline progress
Argenx says its Vision 2030 plan targets treating 50,000 patients and 10 diseases, citing strong progress in MG and CIDP and pipeline expansion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARGX cites strong revenue growth and pipeline progress
ARGX says its Vision 2030 targets are advancing, with strong revenue growth and pipeline expansion via new indications and acquisitions. The company highlights VYVGART in MG and CIDP and adds empasiprubart and FB102 to diversify its immunology portfolio.